Body mass index and cancer risk among adults with and without cardiometabolic diseases: evidence from the EPIC and UK Biobank prospective cohort studies.

Fontvieille, Emma; Heath, Alicia K; Kaaks, Rudolf; Weiderpass, Elisabete; Ferrari, Pietro; Christakoudi, Sofia; Aune, Dagfinn; Recalde, Martina; Inan-Eroglu, Elif; Farràs, Marta; Amiano, Pilar; Overvad, Kim; Tjønneland, Anne; Panico, Salvatore; Moreno-Iribas, Conchi; Tin Tin, Sandar; Masala, Giovanna; Viallon, Vivian; Monninkhof, Evelyn M; May, Anne M; Ricceri, Fulvio; Gunter, Marc J; Katzke, Verena; Petrova, Dafina; Chirlaque, María-Dolores; Mellemkjær, Lene; Jansana, Anna; Lennon, Hannah; Cordova, Reynalda; Peruchet-Noray, Laia; Sieri, Sabina; Schulze, Matthias B; Freisling, Heinz

doi:10.1186/s12916-023-03114-z

Items
Marc 21

001			285565
005			20240229155112.0
024	7	_	\|a 10.1186/s12916-023-03114-z \|2 doi
024	7	_	\|a pmid:37993940 \|2 pmid
024	7	_	\|a altmetric:156738436 \|2 altmetric
037	_	_	\|a DKFZ-2023-02431
041	_	_	\|a English
082	_	_	\|a 610
100	1	_	\|a Fontvieille, Emma \|b 0
245	_	_	\|a Body mass index and cancer risk among adults with and without cardiometabolic diseases: evidence from the EPIC and UK Biobank prospective cohort studies.
260	_	_	\|a Heidelberg [u.a.] \|c 2023 \|b Springer
336	7	_	\|a article \|2 DRIVER
336	7	_	\|a Output Types/Journal article \|2 DataCite
336	7	_	\|a Journal Article \|b journal \|m journal \|0 PUB:(DE-HGF)16 \|s 1700748910_19796 \|2 PUB:(DE-HGF)
336	7	_	\|a ARTICLE \|2 BibTeX
336	7	_	\|a JOURNAL_ARTICLE \|2 ORCID
336	7	_	\|a Journal Article \|0 0 \|2 EndNote
520	_	_	\|a Whether cancer risk associated with a higher body mass index (BMI), a surrogate measure of adiposity, differs among adults with and without cardiovascular diseases (CVD) and/or type 2 diabetes (T2D) is unclear. The primary aim of this study was to evaluate separate and joint associations of BMI and CVD/T2D with the risk of cancer.This is an individual participant data meta-analysis of two prospective cohort studies, the UK Biobank (UKB) and the European Prospective Investigation into Cancer and nutrition (EPIC), with a total of 577,343 adults, free of cancer, T2D, and CVD at recruitment. We used Cox proportional hazard regressions to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between BMI and incidence of obesity-related cancer and in turn overall cancer with a multiplicative interaction between BMI and the two cardiometabolic diseases (CMD). HRs and 95% CIs for separate and joint associations for categories of overweight/obesity and CMD status were estimated, and additive interaction was quantified through relative excess risk due to interaction (RERI).In the meta-analysis of both cohorts, BMI (per ~ 5 kg/m2) was positively associated with the risk of obesity-related cancer among participants without a CMD (HR: 1.11, 95%CI: 1.07,1.16), among participants with T2D (HR: 1.11, 95% CI: 1.05,1.18), among participants with CVD (HR: 1.17, 95% CI: 1.11,1.24), and suggestively positive among those with both T2D and CVD (HR: 1.09, 95% CI: 0.94,1.25). An additive interaction between obesity (BMI ≥ 30 kg/m2) and CVD with the risk of overall cancer translated into a meta-analytical RERI of 0.28 (95% CI: 0.09-0.47).Irrespective of CMD status, higher BMI increased the risk of obesity-related cancer among European adults. The additive interaction between obesity and CVD suggests that obesity prevention would translate into a greater cancer risk reduction among population groups with CVD than among the general population.
536	_	_	\|a 313 - Krebsrisikofaktoren und Prävention (POF4-313) \|0 G:(DE-HGF)POF4-313 \|c POF4-313 \|f POF IV \|x 0
588	_	_	\|a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650	_	7	\|a Cardiovascular diseases \|2 Other
650	_	7	\|a Comorbidities \|2 Other
650	_	7	\|a Multimorbidity \|2 Other
650	_	7	\|a Obesity \|2 Other
650	_	7	\|a Obesity-related cancers \|2 Other
650	_	7	\|a Type 2 diabetes \|2 Other
700	1	_	\|a Viallon, Vivian \|b 1
700	1	_	\|a Recalde, Martina \|0 P:(DE-HGF)0 \|b 2
700	1	_	\|a Cordova, Reynalda \|b 3
700	1	_	\|a Jansana, Anna \|b 4
700	1	_	\|a Peruchet-Noray, Laia \|b 5
700	1	_	\|a Lennon, Hannah \|b 6
700	1	_	\|a Heath, Alicia K \|b 7
700	1	_	\|a Aune, Dagfinn \|b 8
700	1	_	\|a Christakoudi, Sofia \|b 9
700	1	_	\|a Katzke, Verena \|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 \|b 10 \|u dkfz
700	1	_	\|a Kaaks, Rudolf \|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a \|b 11 \|u dkfz
700	1	_	\|a Inan-Eroglu, Elif \|b 12
700	1	_	\|a Schulze, Matthias B \|b 13
700	1	_	\|a Mellemkjær, Lene \|b 14
700	1	_	\|a Tjønneland, Anne \|b 15
700	1	_	\|a Overvad, Kim \|b 16
700	1	_	\|a Farràs, Marta \|b 17
700	1	_	\|a Petrova, Dafina \|b 18
700	1	_	\|a Amiano, Pilar \|b 19
700	1	_	\|a Chirlaque, María-Dolores \|b 20
700	1	_	\|a Moreno-Iribas, Conchi \|b 21
700	1	_	\|a Tin Tin, Sandar \|b 22
700	1	_	\|a Masala, Giovanna \|b 23
700	1	_	\|a Sieri, Sabina \|b 24
700	1	_	\|a Ricceri, Fulvio \|b 25
700	1	_	\|a Panico, Salvatore \|b 26
700	1	_	\|a May, Anne M \|b 27
700	1	_	\|a Monninkhof, Evelyn M \|b 28
700	1	_	\|a Weiderpass, Elisabete \|b 29
700	1	_	\|a Gunter, Marc J \|b 30
700	1	_	\|a Ferrari, Pietro \|b 31
700	1	_	\|a Freisling, Heinz \|0 0000-0001-8648-4998 \|b 32
773	_	_	\|a 10.1186/s12916-023-03114-z \|g Vol. 21, no. 1, p. 418 \|0 PERI:(DE-600)2131669-7 \|n 1 \|p 418 \|t BMC medicine \|v 21 \|y 2023 \|x 1741-7015
909	C	O	\|o oai:inrepo02.dkfz.de:285565 \|p VDB
910	1	_	\|a Deutsches Krebsforschungszentrum \|0 I:(DE-588b)2036810-0 \|k DKFZ \|b 10 \|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
910	1	_	\|a Deutsches Krebsforschungszentrum \|0 I:(DE-588b)2036810-0 \|k DKFZ \|b 11 \|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913	1	_	\|a DE-HGF \|b Gesundheit \|l Krebsforschung \|1 G:(DE-HGF)POF4-310 \|0 G:(DE-HGF)POF4-313 \|3 G:(DE-HGF)POF4 \|2 G:(DE-HGF)POF4-300 \|4 G:(DE-HGF)POF \|v Krebsrisikofaktoren und Prävention \|x 0
914	1	_	\|y 2023
915	_	_	\|a JCR \|0 StatID:(DE-HGF)0100 \|2 StatID \|b BMC MED : 2022 \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0200 \|2 StatID \|b SCOPUS \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0300 \|2 StatID \|b Medline \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0320 \|2 StatID \|b PubMed Central \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0501 \|2 StatID \|b DOAJ Seal \|d 2023-05-02T09:07:15Z
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0500 \|2 StatID \|b DOAJ \|d 2023-05-02T09:07:15Z
915	_	_	\|a Peer Review \|0 StatID:(DE-HGF)0030 \|2 StatID \|b DOAJ : Open peer review \|d 2023-05-02T09:07:15Z
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0600 \|2 StatID \|b Ebsco Academic Search \|d 2023-10-25
915	_	_	\|a Peer Review \|0 StatID:(DE-HGF)0030 \|2 StatID \|b ASC \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0199 \|2 StatID \|b Clarivate Analytics Master Journal List \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1050 \|2 StatID \|b BIOSIS Previews \|d 2023-10-25
915	_	_	\|a WoS \|0 StatID:(DE-HGF)0113 \|2 StatID \|b Science Citation Index Expanded \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0150 \|2 StatID \|b Web of Science Core Collection \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1190 \|2 StatID \|b Biological Abstracts \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0160 \|2 StatID \|b Essential Science Indicators \|d 2023-10-25
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1110 \|2 StatID \|b Current Contents - Clinical Medicine \|d 2023-10-25
915	_	_	\|a IF >= 5 \|0 StatID:(DE-HGF)9905 \|2 StatID \|b BMC MED : 2022 \|d 2023-10-25
915	_	_	\|a Article Processing Charges \|0 StatID:(DE-HGF)0561 \|2 StatID \|d 2023-10-25
915	_	_	\|a Fees \|0 StatID:(DE-HGF)0700 \|2 StatID \|d 2023-10-25
920	1	_	\|0 I:(DE-He78)C020-20160331 \|k C020 \|l C020 Epidemiologie von Krebs \|x 0
980	_	_	\|a journal
980	_	_	\|a VDB
980	_	_	\|a I:(DE-He78)C020-20160331
980	_	_	\|a UNRESTRICTED

Library	Collection	CLSMajor	CLSMinor	Language	Author

Marc 21

guest :: login DKFZ
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help